ReviewBritish journal of pharmacology2017
Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.
Review in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis.CNS drugs · 2022Pooled it
- Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.Journal of neurology · 2026Observational
- A new perspective on therapies involving B-cell depletion in autoimmune diseases.Molecular biology reports · 2024Article
- Autoantibodies - enemies, and/or potential allies?Frontiers in immunology · 2022Review
- Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.Frontiers in immunology · 2021Review
- Early Aggressive Treatment Approaches for Multiple Sclerosis.Current treatment options in neurology · 2021Review
- Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Biological characteristics of transcription factor RelB in different immune cell types: implications for the treatment of multiple sclerosis.Molecular brain · 2019Review
- Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis.Frontiers in molecular neuroscience · 2019Article
- Signaling pathways and therapeutic perspectives related to environmental factors associated with multiple sclerosis.Journal of neuroscience research · 2018Review
- Potential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders.PloS one · 2018Article
- Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.British journal of pharmacology · 2017Review
- Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common causes of disability in young adults. Over the last decade, new disease-modifying therapies have emerged, including monoclonal antibodies (mAbs) that provide highly targeted therapies with greater efficacy than platform therapies. In particular, monoclonal antibodies directed against CD20-positive B cells have shown remarkable results in recent clinical trials and renewed interest in the mechanism of B cell-depleting therapies to ameliorate relapse activity and progression in MS. Here, we review the mechanisms of action and clinical evidence of approved and emerging mAbs, with a focus on B cell-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.